FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
After being burned by Point, Lilly is taking a slower approach with Radionetics.
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.